Marcus Quinkler

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9109684/marcus-quinkler-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers
4,879
citations
4,879
h-index
69
g-index

5,916
ext. papers
6
avg, IF
L-index

#	Paper	IF	Citations
92	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors: A Cross-Sectional Multicenter Study <i>Annals of Internal Medicine</i> , 2022 ,	8	2
91	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine <i>Hypertension</i> , 2022 , 101161HYPERTENSIONAHA12219019	8.5	0
90	Adrenal insufficiency. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 19	51.1	12
89	Characterization of patients with adrenal insufficiency and frequent adrenal crises. <i>European Journal of Endocrinology</i> , 2021 , 184, 761-771	6.5	2
88	Physical and Reported Subjective Health Status in 222 Individuals with XY Disorder of Sex Development. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab103	0.4	
87	Medical Therapy of Acromegaly in Germany 2019 - Data from the German Acromegaly Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021 , 129, 216-223	2.3	2
86	Therapeutic Patient Education for Adrenal Insufficiency under COVID-19 Pandemic Conditions. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021 , 129, 241-249	2.3	3
85	Autonomous Cortisol Secretion Influences Psychopathological Symptoms in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e2423-e2433	5.6	3
84	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	4
83	Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	13
82	Residual Corticosteroid Production in Autoimmune Addison Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
81	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020 , 12,	6.6	14
80	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	27
79	Response to Letter to the Editor: "Impaired Glucose Metabolism in Primary Aldosteronism Is Associated with Cortisol Cosecretion". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	1
7 ⁸	Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study. <i>Clinical Endocrinology</i> , 2020 , 92, 284-294	3.4	16
77	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	17
76	Granulomatous hypophysitis causing compression of the internal carotid arteries reversible with azathioprine and rituximab treatment. <i>Pituitary</i> , 2020 , 23, 103-112	4.3	6

(2018-2020)

75	Response to Letter to the Editor: "CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	
74	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 773-781	18.1	56
73	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
72	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression - Lessons from primary aldosteronism. <i>Journal of Psychiatric Research</i> , 2020 , 130, 82-88	5.2	12
71	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	12
70	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
69	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. <i>Hypertension</i> , 2019 , 74, 800-808	8.5	47
68	Daily adjustment of glucocorticoids by patients with adrenal insufficiency. <i>Clinical Endocrinology</i> , 2019 , 91, 256-262	3.4	7
67	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. Journal of Clinical Endocrinology and Metabolism, 2019 , 104, 3192-3202	5.6	37
66	Diagnosis and Management of Adrenal Insufficiency in Children and Adults 2019 , 705-736		
65	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019 , 104, 312-318	5.6	59
64	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019 , 127, 578-584	2.3	8
63	Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations. <i>Clinical Endocrinology</i> , 2018 , 89, 30-35	3.4	34
62	Management of adrenal emergencies in educated patients with adrenal insufficiency-A prospective study. <i>Clinical Endocrinology</i> , 2018 , 89, 22-29	3.4	17
61	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1686-1695	5.6	66
60	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. <i>European Journal of Endocrinology</i> , 2018 , 178, 605-611	6.5	17
59	Adrenal disease: Imitating the cortisol profile improves the immune system. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 137-139	15.2	6
58	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018 , 71, 317-325	8.5	46

57	Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. <i>Endocrine Connections</i> , 2018 , 7, 811-818	3.5	13
56	Management of adrenal emergencies in educated patients with adrenal insufficiency. prospective study 2018 , 89, 22		1
55	Mortality data from the European Adrenal Insufficiency Registry Patient characterization and associations 2018 , 89, 30		1
54	Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. <i>Clinical Endocrinology</i> , 2017 , 86, 499-505	3.4	5
53	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. <i>European Journal of Endocrinology</i> , 2017 , 176, 737-746	6.5	39
52	Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. <i>Endocrine Connections</i> , 2017 , 6, 1-8	3.5	33
51	I polymorphism of the glucocorticoid receptor and adrenal crisis in primary adrenal insufficiency. <i>Endocrine Connections</i> , 2017 , 6, 685-691	3.5	1
50	Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR. <i>Clinical Endocrinology</i> , 2017 , 86, 340-346	3.4	34
49	In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids. <i>journal of applied laboratory medicine, The,</i> 2017 , 1, 753-755	2	1
48	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2,	9.9	127
48 47	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI</i>		127
	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2,		
47	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2, Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211 Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.	-85	13
47 46	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2, Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211 Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2016 , 174, 531-8 The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency	-85 6.5	13
47 46 45	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2, Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211 Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2016 , 174, 531-8 The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease). <i>Neuroendocrinology</i> , 2016 , 103, 315-20 Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary	- 8 ; 6.5	13 37 13
47 46 45 44	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCl Insight</i> , 2017 , 2, Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211 Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2016 , 174, 531-8 The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease). <i>Neuroendocrinology</i> , 2016 , 103, 315-20 Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2015 , 172, 619-26 Post-saline infusion test aldosterone levels indicate severity and outcome in primary	-8 5 6.5 5.6	13 37 13 74
47 46 45 44 43	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017 , 2, Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211 Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2016 , 174, 531-8 The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease). <i>Neuroendocrinology</i> , 2016 , 103, 315-20 Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2015 , 172, 619-26 Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2015 , 172, 443-50 Diagnostisches und therapeutisches Vorgehen beim Nebennierenrindenkarzinom. <i>Best Practice</i>	-85 6.5 5.6 6.5	13 37 13 74

(2013-2015)

39	Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. <i>Clinical Endocrinology</i> , 2015 , 82, 2-11	3.4	70
38	Cognitive function in patients with primary adrenal insufficiency (Addison's disease). <i>Psychoneuroendocrinology</i> , 2015 , 55, 1-7	5	20
37	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. <i>European Journal of Endocrinology</i> , 2015 , 173, 665-75	6.5	79
36	Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. Journal of Clinical Endocrinology and Metabolism, 2015 , 100, 841-9	5.6	199
35	High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 407-16	5.6	210
34	Saving lives of patients with adrenal insufficiency: a pan-European initiative?. <i>Clinical Endocrinology</i> , 2014 , 80, 319-21	3.4	16
33	European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. <i>BMC Endocrine Disorders</i> , 2014 , 14, 40	3.3	20
32	Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts. <i>PLoS ONE</i> , 2014 , 9, e88991	3.7	25
31	Sleep quality in patients with primary aldosteronism. <i>Hormones</i> , 2014 , 13, 57-64	3.1	5
30	Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1035-9	5.6	74
29	Sexual well-being in adult male patients with congenital adrenal hyperplasia. <i>International Journal of Endocrinology</i> , 2014 , 2014, 469289	2.7	9
28	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study <i>Journal of Clinical Oncology</i> , 2014 , 32, 4106-4106	2.2	
27	Glucagonoma-induced acute heart failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2014 , 2014, 140061	1.4	3
26	Bcll polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy. <i>Clinical Endocrinology</i> , 2013 , 78, 831-7	3.4	18
25	Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5Freductase, explaining the need for personalized glucocorticoid and androgen replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 161-71	5.6	104
24	The role of surgery in the management of recurrent adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 181-91	5.6	110
23	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2013 , 168, 75-81	6.5	50
22	Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. <i>European Journal of Endocrinology</i> , 2013 , 169, R165-75	6.5	81

21	Adrenal cortical insufficiencya life threatening illness with multiple etiologies. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013 , 110, 882-8	2.5	32
20	The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1606-14	5.6	243
19	What is the best long-term management strategy for patients with primary adrenal insufficiency?. <i>Clinical Endocrinology</i> , 2012 , 76, 21-5	3.4	33
18	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2012 , 167, 35-42	6.5	79
17	Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3495-503	5.6	115
16	Combination chemotherapy in advanced adrenocortical carcinoma. <i>New England Journal of Medicine</i> , 2012 , 366, 2189-97	59.2	510
15	What is the best long-term management strategy for patients with primary adrenal insufficiency? 2012 , 76, 21		1
14	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2011 , 75, 585-91	3.4	87
13	Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. <i>Clinical Endocrinology</i> , 2010 , 72, 297-304	3.4	109
12	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. <i>European Journal of Endocrinology</i> , 2010 , 162, 597-602	6.5	209
11	Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4925-32	5.6	118
10	Treatment of primary aldosteronism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010 , 24, 923-32	6.5	17
9	Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. <i>American Journal of the Medical Sciences</i> , 2010 , 339, 525-31	2.2	129
8	Deficits in the management of patients with adrenocortical carcinoma in Germany. <i>Deutsches A&#x0308;rzteblatt International</i> , 2010 , 107, 885-91	2.5	34
7	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. <i>Cancer</i> , 2009 , 115, 243-50	6.4	446
6	The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. <i>Deutsches A&#x0308;rzteblatt International</i> , 2009 , 106, 305-11	2.5	34
5	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2057-62	5.6	122
4	Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. <i>European Journal of Endocrinology</i> , 2008 , 159, 811-7	6.5	81

LIST OF PUBLICATIONS

3	Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3912-22	5.6	201
2	11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 5695-701	5.6	108
1	Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4165-71	5.6	43